<DOC>
	<DOCNO>NCT02186535</DOCNO>
	<brief_summary>The purpose study assess impact approximately 8 week Vitamin D ( VitD ) calcium supplementation , use daily versus weekly supplementation regimen , female reproductive tract immunity .</brief_summary>
	<brief_title>The Role Vitamin D Female Reproductive Tract Immunity</brief_title>
	<detailed_description>This outpatient open label study assess impact 8 week daily versus weekly VitD calcium supplementation measure cervicovaginal ( CV ) innate immune function , include antimicrobial proinflammatory gene expression , Toll-like receptor ( TLR ) -mediated response , immunohistochemical ( IHC ) analysis immune cell marker , microbiota premenopausal woman insufficient serum VitD level baseline . Women see 3 study visit contact one schedule follow-up telephone call final study visit . Volunteers consent Visit 1 undergo procedure confirm eligible continue study . Once confirm participant meet inclusion criterion none exclusion criterion , baseline blood genital sample take luteal phase Visit 2 . The participant give first dose VitD 4000 IU daily 50,000 IU weekly capsule form , administer 8 week . Participants also administer 1000 mg calcium daily . Participants return upon completion supplementation repeat blood genital sample ( Visit 3 ) .</detailed_description>
	<mesh_term>Vitamin D Deficiency</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<criteria>Serum 25 ( OH ) D ≤ 25ng/mL ( 62 nmol/L ) In good health , evidence history procedure screen visit without clinically significant systemic disease . Not risk STI , meaning : In monogamous heterosexual sex relationship partner know HIV positive know risk STIs , Sexually abstinent Willing able comply study procedures 21 50 year age Not risk pregnancy , meaning : Protected pregnancy due surgical sterilization participant sexual partner , Consistent condom use , In sex relationship , Abstinent sexual activity planning remain abstinent duration study Regular menstrual cycle ( every 21 35 day ) past two cycle , per participant report Willing use sunscreen SPF15 high expose sun least 15 minute , avoid use nonstudy Vitamin D , calcium , multivitamin supplementation . A clinically significant history abnormal Pap test ( write report ) past year evaluate and/or treat , indicate , accord standard guideline Surgery biopsy vagina cervix within 14 day Current STI low genital tract infection include HIV1 , Chlamydia trachomatis ( CT ) , Trichomonas vaginalis ( TV ) , Neisseria Gonorrhoeae ( NG ) , Hepatitis B , yeast vaginitis bacterial vaginosis ( BV ) ( Nugent score 7 10 ) ; include asymptomatic HSV human papilloma virus ( HPV ) Current presence vulvar , anal and/or vaginal genital wart Current tobacco use amount Body Mass Index ( BMI ) ≥ 35 kg/m2 History sensitivity/allergy component study product , topical anesthetic , allergy silver nitrate and/or Monsel 's solution Known bleeding disorder could lead prolonged continuous bleed biopsy , take anticoagulant drug Grade 2 high laboratory abnormality , per August 2009 update DAIDS Table Grading Severity Adverse Events Systemic use last two week anticipate use study follow : corticosteroid , nonsteroidal antiinflammatory drug ( NSAIDs ) , antibiotic , anticoagulant drug know prolong bleed and/or clotting , antifungal , antiviral ( e.g. , acyclovir valacyclovir ) antiretrovirals ( e.g. , Viread ) . Note : Participants avoid NSAIDS except treatment dysmenorrhea menses . Participants may use acetaminophen asneeded daily basis study . Known risk factor hypercalcemia ( e.g . malignancy granulomatous disease ) malabsorption syndrome ( e.g . celiac disease , radiation enteritis , active inflammatory bowel disease ) . Other condition , opinion investigator , would constitute contraindication participation study would compromise ability comply study protocol , major chronic illness include limited cancer , serious autoimmune disease , metabolic disorder major psychiatric disorder ( e.g. , schizophrenia ) Current participation drug device study , study , opinion investigator , would jeopardize interpretation result study Use depot medroxyprogesterone acetate ( DMPA ) last six month Use hormonal contraceptive method ( oral , transdermal , transvaginal , implant , intrauterine device ) without 2 subsequent , normal menses since stop hormonal contraceptive Current use copper IUD Currently pregnant pregnancy within past 3 month Currently breastfeed breastfed infant last two month</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>